Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Cohen, Matan J ^a   Sahar, Tali ^b   Benenson, Shmuel ^a   Elinav, Eran ^c   Brezis, Mayer ^a   Soares Weiser, Karla ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d Enhance Reviews   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFONICID; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NEOMYCIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; EPIGASTRIC PAIN; ESOPHAGUS CANDIDIASIS; FATIGUE; FECES ANALYSIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERSOMNIA; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; META ANALYSIS; MONOTHERAPY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70349123018     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004791.pub2     Document Type: Review

References (59)

1. Alvarez RF, Mattos AA, Correa EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arquivos de Gastroenterologia [Archives of Gastroenterology] 2005;42:256-262 (Pubitemid 43231959)
2. Bauer TM, Follo A, Navasa M, Vila J, Planas R, Clemente G, et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Digestive Diseases and Sciences 2002;47:1356-1361 (Pubitemid 34606641)
3. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824 (Pubitemid 47374144)
4. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-724 (Pubitemid 20349256)
5. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. Journal of Hepatology 1998;29:430-436 (Pubitemid 28396660)
6. Rolachon A, Cordier L, Bacq Y,Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22:1171-1174
7. Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis. Annals of Internal Medicine 1995;122:595-598
8. Soriano G,Guarner C, Teixido M, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-481
9. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study. Journal of Hepatology 2008;48:774-779
10. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25: 532-536 (Pubitemid 27106428)
11. Sandhu BS, Gupta R, Sharma J, Singh J,Murthy NS, Sarin SK.Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. Journal of Gastroenterology and Hepatology 2005;20:599-605. (Pubitemid 40755274)
12. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-1138 (Pubitemid 23090768)
13. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-1834
14. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998;59 Suppl 2:54-57 (Pubitemid 28372172)
15. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. Hepatology 1999;29:1655-1661 (Pubitemid 29247035)
16. Bonten MJM, Kreuger WA. Selective decontamination of the digestive tract: cumulating evidence, at last?. Seminars in Respiratory and Critical Care Medicine 2006;27:18-22. (Pubitemid 43334726)
17. Borzio M, Salerno F, Saudelli M, Galvagno D, Piantoni L, Fragiacomo L. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.. Italian Journal of Gastroenterology and Hepatology 1997;29(3):262-266 (Pubitemid 28058783)
18. Campillo B,Dupeyron C, Richardet JP,Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clinical Infectious Diseases 1998;26(5):1066-1070 (Pubitemid 28215464)
19. Chavez-Tapia NC, Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858]
20. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. American Journal of Gastroenterology 1998;93:1895-1900 (Pubitemid 29071701)
21. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011-1016 (Pubitemid 37186877)
22. de Jonge E. Effects of selective decontamination of digestive tract on mortality and antibiotic resistance in the intensive-care unit. Current Opinion in Critical Care 2005;11:144-149
23. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315:629-634 (Pubitemid 27387172)
24. File TM. Hospital-acquired (nosocomial) pneumonia in adults. In: Rose BD editor(s). UpToDate. Waltham, MA, 2007.
25. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501 (Pubitemid 24359062)
26. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995;108:1835-1841
27. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen and the Cochrane Hepato-Biliary Group. About The Cochrane Collaboration. Cochrane Review Groups (CRGs) 2009; Vol.1.
28. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press, 1985.
29. Inadomi J, Sonnenberg A.Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997;113:1289-1294 (Pubitemid 27418983)
30. Iyengar S,Greenhouse JB. Selection models and the file drawer problem. Statistical Science 1988;3:109-117
31. Kjaergard LL, Villumsen J,Gluud C. Reportedmethodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-989
32. Llovet JM, Rodriguez Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. Journal Hepatology 1997;26(1):88-95. (Pubitemid 27072609)
33. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352: 609-613 (Pubitemid 28380142)
34. Mowat C, Stanley AJ. Spontaneous bacterial peritonitis - diagnosis, treatment and prevention. Alimentary Pharmacology & Therapeutics 2001;15:1851-1859 (Pubitemid 34014339)
35. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA, USA: NCCLS, 2007.
36. Ortiz J, Vila MC, Soriano G, Minana J, Gana J, Mirelis B, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999;29(4):1064-1069 (Pubitemid 29168737)
37. Orwin R. A fail-safe N for effect size in meta-analyses. Journal of Educational Statistics 1983;8:157-159
38. Parsaud R. Misleading meta-analysis. "Fail safe N" is a useful mathematical measure of the stability of results. BMJ (Clinical Research Ed.) 1996;312:125.
39. Rimola A,Garcia-Tsao G,Navasa M, Piddock LJV, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology 2000; 32:142-153 (Pubitemid 30039459)
40. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;15:1343-1348
41. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171-175 (Pubitemid 18092078)
42. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. Journal of Hepatology 1994;21:792-796 (Pubitemid 24374146)
43. Schulz KF,Chalmers I,Hayes RJ, Altman DG. Empirical evidence of bias. dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273:408-412
44. Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioural sciences. 2nd Edition. New York: McGraw Hill International, 1988.
45. Silvesteri L, Petros A, Viviani M, Rommes JH, van Saene HKF. Selective decontamination of the digestive tract and ventilator-associated pneumonia. Respiratory Care 2006;51:67-68 (Pubitemid 47471708)
46. Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002907]
47. Soares-Weiser K, Brezis M, Tur-Kaspa R, Paul M, Yahav J, Leibovici L. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scandinavian Journal of Gastroenterology 2003;38(2):193-200. (Pubitemid 36349932)
48. Soriano G, Teixido M, Guarner C, Such J, Espinos JC, Sainz S. Variation of C3 in ascitic fluid from cirrhotic patients subjected to intestinal sterilization or selective intestinal decontamination. Revista Espanola de Enfermedades Digestivas 1989;75(2):123-126
49. Soriano G, Guarner C, Tomas A, Anguera A, Mirelis B, Fernandez C, et al. The duration of the effect of norfloxacin on the fecal flora in cirrhosis patients. Revista Espanola de Enfermedades Digestivas 1992; 81(5):322-326
50. Stoutenbeek CP, Van Saene HKF, Little RA, Whitehead A, and the Working Group on Selective Decontamination of the Digestive Tract. The effect of selective decontamination of the digestive tract on mortality in multiple trauma patients: a multicenter randomized controlled trial. Intensive Care Medicine 2007;33:261-270
51. Thadepalli H, Lou MA, Prabhala RH, Mandal AK. Human intestinal tissue antibiotic concentrations. Clindamycin, gentamicin, and mezlocillin. The American Surgeon 1990;56(11):655-658
52. Tito L, Rimola A, Gines P, Llach J, Arroyo, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31. (Pubitemid 18092054)
53. Toledo C, Salmeron JM, Rimola A, Navasa M, Arroyo V, Llach J, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-257 (Pubitemid 23046697)
54. Tomas A, Soriano G, Guarner C, Teixido M, Mendez C, Tena F, et al. An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination. Revista Espanola de Enfermedades Digestivas 1991;79(4):259-264
55. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplantion 2004;33:735-739 (Pubitemid 38499928)
56. van Belkum A, Vos MC. Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24:109-110
57. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-605
58. Younossi ZM,McHutchison JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. Journal of Hepatology 1997;27:295-298 (Pubitemid 27366209)
59. Zar JH. Biostatistical Analysis. 4th Edition. Prentiss Hall, 1998. * Indicates the major publication for the study